These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 29661870)

  • 1. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
    Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.
    Yagi K; Ishii M; Namkoong H; Asami T; Iketani O; Asakura T; Suzuki S; Sugiura H; Yamada Y; Nishimura T; Fujiwara H; Funatsu Y; Uwamino Y; Kamo T; Tasaka S; Betsuyaku T; Hasegawa N
    BMC Infect Dis; 2017 Aug; 17(1):558. PubMed ID: 28793869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
    Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.
    Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N
    BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D; Lange C
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
    Khan O; Chaudary N
    Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.
    Olivier KN; Shaw PA; Glaser TS; Bhattacharyya D; Fleshner M; Brewer CC; Zalewski CK; Folio LR; Siegelman JR; Shallom S; Park IK; Sampaio EP; Zelazny AM; Holland SM; Prevots DR
    Ann Am Thorac Soc; 2014 Jan; 11(1):30-5. PubMed ID: 24460437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.
    Olivier KN; Griffith DE; Eagle G; McGinnis JP; Micioni L; Liu K; Daley CL; Winthrop KL; Ruoss S; Addrizzo-Harris DJ; Flume PA; Dorgan D; Salathe M; Brown-Elliott BA; Gupta R; Wallace RJ
    Am J Respir Crit Care Med; 2017 Mar; 195(6):814-823. PubMed ID: 27748623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
    Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
    Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
    Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.
    Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.
    Choi H; Jhun BW; Kim SY; Kim DH; Lee H; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):293-295. PubMed ID: 29329759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease.
    Kwon YS; Koh WJ
    J Korean Med Sci; 2016 May; 31(5):649-59. PubMed ID: 27134484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex.
    Zhang Z; Lu J; Song Y; Pang Y
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):31-34. PubMed ID: 29089153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.
    Chu HS; Chang SC; Shen EP; Hu FR
    PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Detection of Clarithromycin and Amikacin Resistance in Mycobacterium abscessus Complex by High-Resolution Melting Curve Analysis.
    Li H; Mulati G; Shang Y; Yao C; Wang Y; Ren W; Xue Z; Li S; Pang Y
    Microbiol Spectr; 2022 Jun; 10(3):e0057422. PubMed ID: 35638787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D; Lange C
    Pneumologie; 2020 Nov; 74(11):773-779. PubMed ID: 33202438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.
    Urabe N; Sakamoto S; Tokita N; Yoshida H; Usui Y; Shimizu H; Sekiya M; Miyoshi S; Nakamura Y; Isobe K; Kishi K
    BMC Pulm Med; 2024 Sep; 24(1):442. PubMed ID: 39256717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.
    Aznar ML; Marras TK; Elshal AS; Mehrabi M; Brode SK
    BMC Pharmacol Toxicol; 2019 Jun; 20(1):37. PubMed ID: 31159865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.